• Roche (Switzerland)
  ThromboGenics and BioInvent entered into a license agreement with Roche for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels.
• Rhein Minapharm (Egypt/Middle East)
  ThromboGenics and Rhein Minapharm entered into a license agreement for manufacturing, clinical development and commercialization of THR-174, the next-generation derivative of Staphylokinase, in the Middle East, Africa and other countries comprising the MENA region. THR-174 is a recombinantly derived thrombolytic agent developed for treatment of acute myocardial infarction (heart attack).
• Bharat Biotech International Limited (India)
  ThromboGenics and Bharat Biotech International Limited entered into a license agreement for manufacturing, clinical development and commercialization of THR-100*, a novel variant of Recombinant Staphylokinase, in developing countries and certain industrialized countries. THR-100 is a thrombolytic agent developed for treatment of acute myocardial infarction (heart attack) and other vascular diseases based on its ability to dissolve blood clots.
  * formerly known as Sak42D
• BioInvent International AB (Sweden)
  ThromboGenics and BioInvent International AB entered into a collaborative research and licensing agreement in September 2004 to co-develop antibody-based drugs for vascular indications. Currently, the partners are jointly developing two candidates:
  TB-402 (Anti-Factor VIII) as an anticoagulant therapy for numerous indications, including prevention and treatment of deep vein thrombosis and treatment of atrial fibrillation; and
  TB-403 (Anti-PlGF) as an anti-angiogenic agent for potential treatment of various diseases, including cancer, age-related macular degeneration, retinopathies and inflammation.
• Millipore Corporation (USA)
  ThromboGenics and Millipore Corporation entered into a license agreement under which ThromboGenics has licensed its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(TM)*. The technology for producing RESGRO was originally developed by the ThromboGenics drug discovery team as part of its successful efforts to identify several of its drug discovery candidates currently in clinical trials.
  * RESGRO and Chemicon are Milipore owned trademarks. RESGRO is also known as TX-WES Stem Cell Medium
• Roche Diagnostics (Switzerland) and Biosite Inc. (USA)
  ThromboGenics, along with its partner Geymonat, has entered into two co-exclusive licensing agreements, with Roche Diagnostics and Biosite Inc., for use of PlGF (Placental Growth Factor) in diagnostic applications. ThromboGenics and Geymonat have out-licensed the use of PlGF as a diagnostic marker for the prediction of major cardiac events, such as heart attack, and pre-eclampsia, a disease of pregnancy.
• Geymonat SpA (Italy)
  ThromboGenics and Geymonat SpA entered into a cooperation agreement for co-development of PlGF (Placental Growth Factor) in February 2004, as a pro-angiogenic growth factor which has shown potential in pre-clinical studies to treat conditions such as ischemic heart disease.
  The objective of this collaboration is to bring together into a single intellectual property portfolio the patents covering both the composition-of-matter and use of PlGF. Geymonat owns the exclusive rights to the intellectual property characterising the protein sequence of PlGF. ThromboGenics owns the exclusive rights to the therapeutic applications of PlGF.
• NuVue Technologies Inc. (USA)
  In March 2004, ThromboGenics and NuVue Technologies Inc. entered into a licensing and collaboration agreement for development of plasmin-based products as candidates to treat serious visual disorders. ThromboGenics received an exclusive license to all current, pending and future NuVue Technologies intellectual property, including data and know-how, related to the use of plasmin for ophthalmic applications.
  The objective of this collaboration is to bring into a single portfolio all relevant intellectual property relating to the manufacture and use of plasmin-based compounds for treatment of eye diseases. This agreement eliminates a potential intellectual property hurdle, and firmly establishes ThromboGenics’ freedom-to-operate in this field.

Academic

ThromboGenics has a wide range of agreements with numerous academic institutes that have significant research expertise in the vascular area, and from which the Company has in-licensed a number of the therapeutic programmes that it currently has under development. These academic institutes include:

• Center For Molecular and Vascular Biology, KULeuven
  The Company has two collaborations on projects that are in-licensed from this academic center, the development of microplasmin, staphylokinase, Anti-Factor VIII and Anti-VPAC.
• Flanders Institute for Biotechnology (VIB)
  The Company has an ongoing collaboration with the Center for Transgene Technology and Gene Therapy, a department of the VIB, on the pre-clinical characterisation of two of its programmes that were in-licensed from this institute, Anti-PlGF and PlGF.
• Scientific Advisory Boards
  In addition to the above collaborations, ThromboGenics has Advisory Boards for several of its advanced programmes (namely, the Microplasmin-Vitreoretinal Advisory Board, the Microplasmin-Stroke Advisory Board, the Anti-Factor VIII Advisory Board, and the Anti-PlGF Advisory Board).